Literature DB >> 23456225

Lymph node ratio may be supplementary to TNM nodal classification in node-positive breast carcinoma based on the results of 2,151 patients.

Nüvit Duraker1, Bakir Bati, Zeynep Civelek Çaynak, Davut Demir.   

Abstract

BACKGROUND: The aim of the present study was to determine how lymph node ratio (LNR; the ratio of the number of metastatic lymph nodes to the number of removed lymph nodes) can supplement the TNM nodal classification in breast carcinoma.
METHODS: We retrospectively reviewed the file records of 2,151 patients.
RESULTS: Lymph node ratio-based low- (LNR ≤ 0.20), intermediate- (LNR 0.21-0.65), and high-risk (LNR > 0.65) patient groups had significantly different disease-free survival (DFS) (P < 0.001). The DFS of patients with N1, N2, and N3 disease was significantly different (P < 0.001). When LNR and TNM nodal groupings were included together in the Cox analysis, both groupings had independent prognostic significance (P < 0.001 and P < 0.001, respectively). The most significant LNR threshold value separating patients in low-risk and high-risk groups in terms of disease recurrence was 0.20 for N1 disease (P < 0.001), 0.35 for N2 disease (P < 0.001), and 0.90 for N3 disease (P < 0.001).
CONCLUSIONS: Lymph node ratio and TNM nodal groupings show no superiority over each other in categorizing patients with node-positive breast carcinoma into prognostic groups of low-, intermediate-, and high-risk. However, LNR grouping may supplement TNM nodal classification by categorizing patients within each TNM nodal group into low-risk and high-risk groups with significantly different survival.

Entities:  

Mesh:

Year:  2013        PMID: 23456225     DOI: 10.1007/s00268-013-1965-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  37 in total

Review 1.  Prognostic value of nodal ratios in node-positive breast cancer.

Authors:  Wendy A Woodward; Vincent Vinh-Hung; Naoto T Ueno; Yee Chung Cheng; Melanie Royce; Patricia Tai; Georges Vlastos; Anne Marie Wallace; Gabriel N Hortobagyi; Yago Nieto
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

2.  The impact of the number of excised axillary nodes and of the percentage of involved nodes on regional nodal failure in patients treated by breast-conserving surgery with or without regional irradiation.

Authors:  André Fortin; Anne Dagnault; Lucie Blondeau; Thi Trinh Thuc Vu; Marie Larochelle
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-15       Impact factor: 7.038

3.  The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.

Authors:  Pauline T Truong; Eric Berthelet; Junella Lee; Hosam A Kader; Ivo A Olivotto
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

4.  Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients.

Authors:  Suzanne C Schiffman; Kelly M McMasters; Charles R Scoggins; Robert C Martin; Anees B Chagpar
Journal:  J Am Coll Surg       Date:  2011-05-20       Impact factor: 6.113

5.  Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.

Authors:  C Schmoor; W Sauerbrei; G Bastert; H Bojar; M Schumacher
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

Review 6.  Lymph-node dissection in breast cancer.

Authors:  A Bembenek; P M Schlag
Journal:  Langenbecks Arch Surg       Date:  2000-07       Impact factor: 3.445

7.  Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer.

Authors:  Luciano José Megale Costa; Heloisa Prado Soares; Heloisa Amaral Gaspar; Luciana Garcia Trujillo; Patrícia Xavier Santi; Rafaela Sarmento Pereira; Thaís Lins de Santana; Fernanda Nunes Pinto; Auro del Giglio
Journal:  Am J Clin Oncol       Date:  2004-06       Impact factor: 2.339

8.  Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma?

Authors:  Nüvit Duraker; Zeynep C Caynak; Bakir Bati
Journal:  Ann Surg Oncol       Date:  2007-10-03       Impact factor: 5.344

9.  Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer.

Authors:  David W Petrik; David R McCready; Carol A Sawka; Vivek Goel
Journal:  J Surg Oncol       Date:  2003-02       Impact factor: 3.454

10.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Authors:  B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

View more
  6 in total

1.  Prognostic value of the lymph node ratio for lymph-node-positive breast cancer- is it just a denominator problem?

Authors:  Upali W Jayasinghe; Nirmala Pathmanathan; Elisabeth Elder; John Boyages
Journal:  Springerplus       Date:  2015-03-11

2.  Metastatic axillary node ratio predicts recurrence and poor long-term prognosis in patients with advanced stage IIIC (pN3) breast cancer.

Authors:  Min Hee Hur; SeungSang Ko
Journal:  Ann Surg Treat Res       Date:  2017-04-27       Impact factor: 1.859

3.  How many ELNs are optimal for breast cancer patients with more than three PLNs who underwent MRM? A large population-based study.

Authors:  Xiaohui Wang; Changbin Ji; Huiying Chi; Haiyong Wang
Journal:  Onco Targets Ther       Date:  2018-02-26       Impact factor: 4.147

4.  Breast Cancer Patients With Positive Apical or Infraclavicular/Ipsilateral Supraclavicular Lymph Nodes Should Be Excluded in the Application of the Lymph Node Ratio System.

Authors:  Zhe Wang; Wei Chong; Huikun Zhang; Xiaoli Liu; Yawen Zhao; Zhifang Guo; Li Fu; Yongjie Ma; Feng Gu
Journal:  Front Cell Dev Biol       Date:  2022-04-04

5.  Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

Authors:  Yun Yeong Kim; Heung Kyu Park; Kyung Hee Lee; Kwan Il Kim; Yong Soon Chun
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

6.  The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based study.

Authors:  Huiying Chi; Chenyue Zhang; Haiyong Wang; Zhehai Wang
Journal:  Oncotarget       Date:  2017-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.